Merck to Acquire Unity-SC, Enhancing AI-Enabled Semiconductor Solutions
Merck, a leading science and technology company, plans to acquire Unity-SC, a provider of metrology and inspection instruments for the semiconductor industry. The deal includes an initial payment of €155…
Merck Launches First GMP-Compliant Cell Culture Media Production Line in China
Merck, a leader in science and technology, has announced the launch of its first GMP (Good Manufacturing Practices) compliant cell culture media (CCM) manufacturing line in China. The new facility,…
EMA Validates Bristol Myers’ Opdivo + Yervoy for Advanced Liver Cancer
Bristol Myers Squibb today announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line treatment for…
Bristol Myers Squibb Achieves Significant Environmental Sustainability Milestone
Bristol Myers Squibb today announced the validation of its near-term and net-zero science-based targets by the Science Based Targets initiative (SBTi) as part of a mid-year update on its environmental…
New Data Shows Sustained Efficacy of Roche’s Susvimo in Two Serious Diabetic Eye Conditions
Roche announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for treating diabetic macular edema (DME) and diabetic retinopathy (DR),…
Roche’s Vabysmo Proves Durable and Effective in Long-Term DME Study
Roche announced new, four-year data from the RHONE-X extension study today. The study met all primary endpoints, demonstrating that Vabysmo® (faricimab) was well tolerated in people with diabetic macular edema…
Roche Announces Positive Phase I Results for Obesity Treatment CT-996
Roche announced positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist for treating type…
Zura Bio Initiates Warrant Exchange Offer and Seeks Consent
Zura Bio, a clinical-stage immunology company specializing in dual-pathway antibodies for autoimmune and inflammatory diseases, has announced the commencement of an exchange offer (the “Offer”) and consent solicitation (the “Consent…
RAS(ON) Inhibitors Show Strong Anti-Tumor Activity in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
Revolution Medicines, a clinical-stage oncology company dedicated to targeting RAS-addicted cancers, has announced the publication of a peer-reviewed research paper in Cancer Discovery. The paper showcases the efficacy of their…
Lupin Secures U.S. FDA Approval for Topiramate Extended-Release Capsules
Global pharmaceutical leader Lupin Limited (Lupin) has announced the approval of its Abbreviated New Drug Application by the United States Food and Drug Administration (U.S. FDA) for Topiramate Extended-Release Capsules.…
Lupin Limited Receives EIR from U.S. FDA for Dabhasa Facility
Global pharmaceutical leader Lupin Limited announced today that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility…
WHO Introduces Innovative Training Course to Empower Parliamentarians in Global Health Security
The World Health Organization has released “The Role of Parliaments and Parliamentarians in Strengthening Health Security Preparedness,” an online training course designed to equip parliamentarians with the knowledge and tools…